Please note: Our next Awareness Night is Wed. Nov. 22, not Nov. 29 as has appeared in some places.

Hormone Therapy

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

July 2, 2017

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. Read the […]

Read the article or watch the video →

Biolyse Pharma stymied in effort to make cheaper version of pricey prostate cancer drug

April 9, 2017

A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price. Right now Xtandi costs U.S. patients as much as $129,000 US a year, or about $90 per pill. St. Catharines, Ont.-based Biolyse Pharma says it can make the […]

Read the article or watch the video →

Psychological Effects From ADT a Growing Challenge in Prostate Cancer

February 19, 2017

Androgen-deprivation therapy (ADT) can be associated with significant psychological effects in patients with prostate cancer. Additionally, these side effects—which include depression, Alzheimer disease, and coronary disease—are often under-reported by patients. Read the article here.

Read the article or watch the video →

Prostate Cancer Treatment Can Raise Dementia Risk

February 19, 2017

Reducing testosterone levels with androgen deprivation therapy, or A.D.T., is a common treatment for prostate cancer. But a new study has found that it more than doubles the risk of dementia. Read the article here.

Read the article or watch the video →

ADT May Increase Depression Risk in Prostate Cancer

July 3, 2016

When elderly men with localized prostate cancer are given androgen-deprivation therapy (ADT), the risk of depression and hospitalization for psychiatric treatment is significantly increased, a population-based study of 78,000 U.S. men showed. Read the article.

Read the article or watch the video →

Common prostate cancer treatment may double Alzheimer’s risk

March 6, 2016

The results of a study support an association between the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer and an increased risk of Alzheimer’s disease in a general population cohort. Read the article.

Read the article or watch the video →

Video: Dr. Shabbir Alibhai, “Understanding, preventing and managing side effects of hormone therapy.”

March 4, 2016

January 2016 Awareness Night   Understanding, preventing and managing side effects of hormone therapy. Dr. Shabbir Alibhai,MSc, MD, FRCPC,Princess Margaret Cancer Centre Senior Scientist, Toronto General Research Institute (TGRI) Scientist, Toronto Rehabilitation Institute (TRI) Asst Prof, Depts of Medicine and Health Policy, Management, and Evaluation at the U of Toronto CLICK ON THE ARROW TO […]

Read the article or watch the video →

Prostate cancer survivors more likely to die of other diseases

February 15, 2016

Prostate cancer survivors are most likely to die from something other than cancer, with cardiovascular disease as the most common cause, according to a new study. Androgen deprivation therapy, or ADT, may increase several cardiovascular risk factors that contribute to heart disease and adverse cardiovascular events, researchers at Vanderbilt University report. Read the article.

Read the article or watch the video →

Video: Dr. Gerard Morton, “Radiation and Hormone Therapy”

December 14, 2015

July 2015 Scotiabank Awareness Night   Radiation and Hormone Therapy Dr. Gerard Morton, MB BCh BAO, MRCPI, FRCPC, FFRRCSI Associate Professor , Department of Radiation Oncology, University of Toronto Radiation Oncologist, Sunnybrook Odette Cancer Centre Head of Brachytherapy, Sunnybrook Odette Cancer Centre Chair,  Ontario Association of Radiation Oncologists Affiliate scientist, Evaluative Clinical Sciences, Odette Cancer […]

Read the article or watch the video →

Long-term ADT Best for Locally Advanced Prostate Cancer

November 1, 2015

Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally advanced prostate cancer treated with radiotherapy. Read the article.

Read the article or watch the video →